Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.

You may also be interested in...



AstraZeneca Staking Its Growth On Oncology; Now It Needs Cancer Drugs

AstraZeneca has an ambitious agenda to become a leader in oncology. The company’s notably improved pipeline is broad, but winning will require AstraZeneca to come from behind to uncover the best combinations ahead of the competition.

AstraZeneca Gives Iressa Another Go In The EU

Filing for marketing authorization in lung cancer comes three years after AstraZeneca initially withdrew its application.

AstraZeneca Gives Iressa Another Go In The EU

Filing for marketing authorization in lung cancer comes three years after AstraZeneca initially withdrew its application.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS058417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel